.jpg "Catalyst Biosciences Inc (NASDAQ: CBIO)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Catalyst Biosciences Inc (NASDAQ: CBIO) and Adamis Pharma (NASDAQ: ADMP) with bullish sentiments.
Catalyst Biosciences Inc (NASDAQ: CBIO)
B.Riley FBR analyst George Zavoico maintained a Buy rating on Catalyst Biosciences Inc (NASDAQ: CBIO) on May 11 and set a price target of $44. The company’s shares opened today at $26.59.
Zavoico said:
“Following a review of corporate activities and 1Q18 financial results by Catalyst Biosciences, Inc., we revised our model and clinical development milestone projections for CB2679d/ISU304 (rFIX) and marzeptacog alfa (MarzAA; rFVIIa) for prophylactic treatment of severe hemophilia B and hemophilia A or B with inhibitors, respectively, by regularly scheduled subcutaneous (SQ) injections. After positive top-line results of a Phase I/II trial of CB2679d/ISU304 were reported in 1Q18, Catalyst Bio added an expansion cohort to evaluate the effects of a loading dose and longer daily dosing on FIX activity levels to better inform and de-risk the design of a planned Phase IIb trial expected to begin in 3Q18. Interim results of this expansion cohort expected in 3Q18 and again in 4Q18.”
According to TipRanks.com, Zavoico is a 2-star analyst with an average return of 0.3% and a 41.8% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Actinium Pharmaceuticals, and Asterias Biotherapeutics.
Currently, the analyst consensus on Catalyst Biosciences Inc is Moderate Buy and the average price target is $75, representing a 182.1% upside.
In a report issued on May 8, Chardan Capital also maintained a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
Adamis Pharma (NASDAQ: ADMP)
In a report released today, Andrew D’silva from B.Riley FBR reiterated a Buy rating on Adamis Pharma (NASDAQ: ADMP), with a price target of $6.25. The company’s shares opened today at $3.80.
D’silva said:
“Corporation (ADMP) filed its 10-Q for 1Q18 AMC, on 5/10. The company does not host a conference call. Its 1Q18 top line/EPS came in at $3.2M/($0.23), compared to our/consensus estimates of $3.1M/($0.22) and $3.9M/($0.13), respectively. There were no meaningful surprises relative to our estimates as the print was largely in line with our projections. The miss relative to the Street was related to lower sales out of the company’s compounding business, as well as opex being modeled too lightly. Meanwhile, ADMP exited 1Q18 with $9.1M in cash, $4.9M in debt, and a current ratio of 1.9:1.0.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 18.8% and a 57.4% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Kindred Biosciences, and Cytosorbents Corp.
Currently, the analyst consensus on Adamis Pharma is Strong Buy and the average price target is $7.41, representing a 95.0% upside.
In a report issued on May 11, Maxim Group also maintained a Buy rating on the stock with a $10 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
